Showing 2141-2150 of 2235 results for "".
- NuEra Tight Radio Frequency Device Now Available from Lumenishttps://modernaesthetics.com/news/nuera-tight-radio-frequency-device-now-available-from-lumenis/2472008/Lumenis has launched NuEra tight, a non-invasive, intelligent temperature-controlled technology for both superficial and deep heating that treats a variety of conditions, such as skin
- Galderma Announces the Start of Six New Aesthetic Studieshttps://modernaesthetics.com/news/galderma-announces-the-start-of-six-new-aesthetic-studies/2472014/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and
- Cellfina Results Last Five Years, New Ultherapy Guidelineshttps://modernaesthetics.com/news/cellfina-results-last-five-years-new-ultherapy-guidelines/2472012/One Cellfina treatment improves the appearance of cellulite on the thighs and buttocks for five years, according to new data presented by Merz
- New Cutera Survey Results Help Define Body Contouring Markethttps://modernaesthetics.com/news/new-cutera-survey-helps-define-body-contouring-market/2472026/One third of Americans opt for body sculpting treatments to look better naked, according to a new survey from Cutera, Inc. The survey results we
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://modernaesthetics.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2472031/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- New for EBD-Based Acne Care: Sebacia Microparticles Clearedhttps://modernaesthetics.com/news/new-for-ebd-based-acne-care-sebacia-microparticles-cleared/2472033/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic
- Allergan Acquires Bonti for $195Mhttps://modernaesthetics.com/news/allergan-acquires-bonti-for-195m/2472036/Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the
- Candela Acquires Ellipsehttps://modernaesthetics.com/news/candela-acquires-ellipse/2472039/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita